NextLevel Pharma organises focused industry webinars that can help you achieve an edge in your business and take your enterprise to the next level.
Every day academics, diagnostic developers, biotech and pharma companies get closer to scientific breakthroughs in technology and methods that are applicable to oncology treatments. Given the sheer volume of such discoveries, it is becoming increasingly difficult for potential stakeholders to become aware of these advances and remain updated. Emerging technology in areas such as nanosciences, medical imaging, bioinformatics, and particle engineering have been combined with medical biology to give rise to a new generation of oncology therapies. Not only have researchers been able to make discoveries that can exploit the cellular and genomic make up of cancer cells, but they are also pioneering methods to deliver such treatments precisely to these cells.
This webinar series gives viewers a chance to hear about cutting edge research from the minds that brought it to life.
This webinar includes the following presentations:
- Next Generation Nano Carriers for Delivery, Imaging and Targeting: biocompatible formulations and processing
- The implications of drug transport and penetration on the efficacy of local chemotherapy: An example of treating brain tumors
- How Nanoparticle-mediated Delivery Could Transform the Therapeutic Potential of Biopharmaceuticals and Failed anti-Cancer Drug Candidates
- From Systemic to Intracellular Targeting of Nanomedicines: the challenge of the immune system
- A Versatile Platform for siRNA Delivery Using Novel Amino Acid Derivatives
- Anti-Cancer Drug Design: The Necessary and Sufficient Conditions
- Image-guided Ultrasound-Triggered Drug Delivery
- Nanoconjugate Drug Delivery System
- A Novel Class Therapeutic to Shrink Tumors and Induce Long Term Immunity
- The Inverse Drug Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: A Treatment for Ovarian Cancer?
- A Simple Prodrug Approach Targeting Neoplastic Cells with Elevated Iron Content
- Prognostic Value of an Activation State Marker for Downstream Pathways of EGFR in Tissue Microarrays of Solid Tumors
- Direct Procaspase-3 Activation as an Anit-Cancer Strategy: Compound Discovery, Mechanism of Action, and a Canine Clinical Trial
- Cancer Genes: Tumor vs. Host?
- Development and Clinical Implementation of a Pathway Biomarker Mapping Technology for Personalized Therapy
The recordings of these webinars are available for purchase. For more details, please contact us at webinars(at)nextlevelpharma.com
04. Dr. Dan Peer - From Systemic to Intracellular Targeting of Nanomedicines: the challenge of the immune system
